Table 2.
Variables associated with US score in patients with Sjögren’s syndrome from analysis of covariance with complete cases.
| Variables | Unadjusted | Adjusted* | ||||
|---|---|---|---|---|---|---|
| Coefficient | 95% CI | p-value | Coefficient | 95% CI | p-value | |
| Age, per 1 year (n = 115) | 0.001 | − 0.04 to 0.04 | 0.96 | |||
| Female (n = 115) | − 0.06 | − 2.8 to 2.69 | 0.97 | |||
| Focus score, per 1 (n = 115) | 0.21 | 0.07 to 0.36 | 0.0035 | 0.27 | 0.06 to 0.49 | 0.015 |
| Xerostomia (+) (n = 113) | 0.5 | − 0.98 to 1.99 | 0.51 | |||
| Xerophthalmia (+) (n = 113) | 0.23 | − 1.09 to 1.54 | 0.74 | |||
| Saxon test (+) (n = 108) | 2.86 | 1.36 to 4.37 | < 0.001 | 2.51 | 1.02 to 3.99 | 0.0013 |
| Schirmer’s test (+) (n = 107) | 0.34 | − 1.04 to 1.72 | 0.63 | |||
| Anti-Ro/SS-A antibody (+) (n = 115) | − 0.14 | − 1.58 to 1.3 | 0.85 | |||
| Anti-La/SS-B antibody (+) (n = 112) | 1.26 | − 0.08 to 2.6 | 0.067 | |||
| Anti-centromere antibody (+) (n = 113) | 2.37 | 0.98 to 3.77 | 0.0012 | 1.73 | 0.31 to 3.16 | 0.019 |
| Serum IgG ≥ 1600 mg/dL (+) (n = 110) | 1.33 | 0.1 to 2.57 | 0.037 | 1 | − 0.18 to 2.17 | 0.099 |
| ClinESSDAI, per 1 (n = 87) | 0.12 | − 0.01 to 0.25 | 0.078 | |||
| ESSDAI, per 1 (n = 87) | 0.14 | − 0.01 to 0.28 | 0.063 | |||
SS, Sjögren's syndrome; CI, confidence interval; IgG, immunoglobulin G; ESSDAI, European League Against Rheumatism; Sjögren's Syndrome Disease Activity Index. *N = 104 for the multivariate analysis. p < 0.05 was considered significant. Bold font indicates significant values.